A Phase 1b-2, Open-Label, Dose-Escalation, Expansion and Optimization Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of LRK-4189 Alone and in Combination With mFOLFOX6 or FOLFIRI in Patients With Solid Tumors
Latest Information Update: 30 Mar 2026
At a glance
- Drugs LRK 4189 (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
- Indications Colorectal cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Larkspur Biosciences
Most Recent Events
- 30 Mar 2026 New trial record